| Date | Title | Description | |
|---|---|---|---|
| 29 Sep 2025 | On corporate transactions: mergers, acquisitions and others | ROVI announces the acquisition of an injectable drug product manufacturing site in Phoenix, Arizona (USA) | Download |
| 29 Sep 2025 | On corporate transactions: mergers, acquisitions and others | The Company releases the presentation related to the acquisition of an injectable drug product manufacturing site in Phoenix, Arizona (USA) | Download |
| 24 Jul 2025 | On P&L | The Company releases the press release related to the first half of 2025 financial results | Download |
| 24 Jul 2025 | On P&L | The Company releases the first half 2025 financial results presentation | Download |
| 25 Mar 2025 | On business and financial situation | The Company releases the presentation related to its strategy update because of its 2025 Capital Markets Day | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 11 Jun 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 7 June 2024 and 11 June 2024 and end of the share buyback program | Download |
| 07 Jun 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 31 May and 6 June 2024 | Download |
| 31 May 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 24 May and 30 May 2024 | Download |
| 24 May 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 17 May and 23 May 2024 | Download |
| 21 May 2024 | Announcement of general shareholders’ meeting | Publication of the announcement of the call to the General Shareholders’ Meeting and the documentation related thereto. | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 06 Apr 2017 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the first quarter of 2017 | Download |
| 13 Mar 2017 | Otros sobre negocio y situación financiera | The Company releases the presentation related to its biosimilar of Enoxaparin | Download |
| 07 Mar 2017 | Otros sobre negocio y situación financiera | ROVI informs that the Decentralised procedure used for the registration of its biosimilar of enoxaparin has been completed with positive outcome | Download |
| 16 Feb 2017 | Otros sobre Gobierno Corporativo | The Company informs about the agreements adopted by the Board of Directors | Download |
| 16 Feb 2017 | Informe anual de remuneraciones de los consejeros | ROVI releases the 2016 annual report regarding remuneration of the members of the Board of Directors | Download |